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The Need for a Blood Substitute 
The search for a blood substitute has been an ongoing research area for 
at least the last twenty-five years due to problems within the blood supply .1 A 
blood substitute would eliminate worries about the spread of infectious diseases 
such as AIDS and hepatitis from the blood supply, blood shortages would not be 
as prevalent, there would be no need to specify blood type, and the blood 
substitute would hopefully have a longer shelf life than fresh blood. However, a 
blood substitute has to possess many of the properties of normal blood. The 
blood substitute would have to be able to transport oxygen to various tissues as 
needed, and be a large-sized molecule so as not to be removed by the kidneys.2 
It would also have to be stable, easily purified from any contaminants, and non-
toxic. 
Hemoglobin, which is contained in red blood cells, would seem to be a 
natural substitute for blood because it is already present in the human body. 
When crosslinked, hemoglobin can also be heated to eliminate any viral 
contaminants. 2 Hemoglobin has two main functions within the human body: a) to 
deliver oxygen to tissues via the binding of oxygen to the heme iron atoms, and 
b) to transport the carbon dioxide byproducts and hydrogen ions from the tissues 
2 
to the lungs in order to eliminate the carbon dioxide as waste. 3 Therefore, 
hemoglobin already functions as an oxygen transporter. 
There are various types of hemoglobin which contain combinations of 
different subunits. Hemoglobin A discussed in this thesis, is 97.5% of the total 
hemoglobin in adult primates.3 Human hemoglobin A is a tetramer of two alpha 
and two beta subunits. Each of the alpha subunits contains 141 amino acid 
residues and each beta subunit has 146 amino residues.4 Each subunit of 
hemoglobin has one heme which consists of a porphyrin ring with one iron atom, 
which is the oxygen binding site. 
One alpha and one beta subunit interact to form a dimer. An alpha 
subunit has few interactions with the other alpha subunit of a tetramer, and the 
same is true for the beta subunits. The major subunit interfaces are a1 ~1, a2~2, 
a1 ~2 and a2~1. 
Hemoglobin exists in two conformations: the R (relaxed) state and the T 
(tense) state. In the T state, the hemoglobin is the deoxyhemoglobin or 
decreased oxygen binding state. Hemoglobin is a very taut or rigid molecule in 
this state due to the formation of eight salt links (electrostatic interactions) as well 
as other hydrogen bonds maintaining the deoxyhemoglobin conformation.3 
In order for the transition to the R or oxyhemoglobin state to occur, some 
of the salt links and hydrogen bonds must be disrupted.3 This allows the 
hemoglobin molecule to move and the oxygen to bind more easily to the iron 
binding site. The binding of oxygen to deoxyhemoglobin is cooperative.3 After 
the first oxygen binds, it then becomes easier for the next oxygen to bind and so 
forth. As stated previously, in the transition from the deoxy to oxy state, the 
hemoglobin molecule has to change conformation. One dimer, a1 ~1. shifts by 15 
3 
degrees relative to the other dimer, a2P2, and the p chains move closer 
together.3 
One problem with the use of hemoglobin as a blood substitute is that in 
the oxyhemoglobin form it will dissociate into dimers and be filtered through the 
kidneys. One way to solve this problem is to use a crosslinker to stabilize the 
tetramers. This crosslinked hemoglobin must then be able to carry out similiar 
functions as normal blood, such as transporting oxygen. Thus the search for the 
best crosslinker of hemoglobin continues. 
History of Hemoglobin Crosslinkers and Allosteric Modifiers 
The majority of the published work with crosslinkers has been due to 
attempts to solve the problem of sickling caused by Hemoglobin S.5-11 However, 
these potential crosslinkers have been tested in both Hemoglobin A and S in 
order to determine the sites of reaction. 
There are many known types of crosslinkers. Schiff base adducts, 12 
aspirin analogues5• 6• 11 • 13-18 and bis-pyridoxal polyphosphates19 are only some 
of the choices. A crosslinker has many possible interaction sites available on 
hemoglobin. The areas of specific interest to us are the bisphosphoglycerate 
(BPG) binding site and the a99 site in oxyhemoglobin and in deoxyhemoglobin. 
Upon binding to the deoxyhemoglobin (T state), BPG 1 bridges the p 
chains, which stabilizes the tetramer in the T state and decreases the oxygen 
affinity. In oxyhemoglobin (R state), the proximity of the p subunits forces the 
BPG out of the binding pocket. Thus, BPG is acting as an allosteric regulator of 




Schiff base adducts are one type of monofunctional crosslinker. Zaugg 
and coworkers examined 31 carbonyl compounds (Figure 1) which react with an 
amino group on the hemoglobin A and S proteins to form reversible Schiff base 
compounds. 12 Aromatic aldehydes produced the greatest changes in 
intracellular hemoglobin in binding of oxygen compared to aliphatic aldehydes 
(less reactive) and ketones (none were reactive). The hemoglobin modified by 
aromatic aldehydes resulted in an increase in oxygen affinity compared to the 
hemoglobin modified by aliphatic aldehydes and ketones which exhibited no 
increase in oxygen affinity. Aromatic aldehydes were suggested to form 
relatively stable bonds in hemoglobin through reaction with an amine of a lysine 
residue. Additionally, the addition of a second functional group on the aromatic 
ring significantly affected the oxygen binding. The rate of the Schiff base 
formation reaction increased when an electron-withdrawing substituent was 
present. Bulky substituents next to the carbonyl prohibited this reaction from 
occuring. Compounds were most potent when there was a hydroxyl group in the 
ortho position. This was suggested to help guide the ligand to a specific site on 
hemoglobin. 
Beddell20· 21 and coworkers used molecular modeling to propose three 
possible compounds that could interact in the BPG binding site of 
5 
FIGURE 1 









































deoxyhemoglobin. Beddell examined the BPG binding in the X-ray crystal 
structure of deoxyhemoglobin.22 Eight nitrogens in the BPG site were further 
examined: two from the terminal amino groups of the p chains, and from His p2, 
Lys P82, and His P143 from each p subunit. A desired characteristic of a ligand 
was a lower polarity than BPG, allowing the compound to cross the red cell 
membrane. Other desired characteristics were that the molecule be novel, 
conformationally limited and easy to synthesize. This molecule was designed to 
react at the terminal amino groups of the p subunits. The starting ligand was one 
proposed by Robertson23 - a bibenzyl structure. Aldehyde groups were added in 
the para positions to enable the molecule to form Schiff bases with the 
deoxyhemoglobin. Unfortunately, this molecule was not soluble in water, so the 
structure was modified to increase solubility resulting in ligand 2. 
2 
Other compounds that were suggested included a bisulphite derivative 3 







Synthesis and testing of these compounds showed the design was successful 
and all the compounds promoted liberation of oxygen from deoxyhemoglobin, 
similar to BPG. 3 was even comparable in potency to BPG as measured by the 
right shift in the oxygen affinity graph, indicating a decrease in oxygen affinity. 
NMR experiments21 provided support for the proposed mode of interaction of 2 
and 3 in the BPG binding site. 
Aspirin and diaspirin analogues have long been known to act as potent 
acylating agents of the amine groups on hemoglobin.5• 6• 11 • 13-18 Aspirin 5 is a 
member of the acylsalicylates group and diaspirin, for example 6, is a double-
headed aspirin with various groups bridging the two aspirin portions. 
COOH 
5 
From these studies much can be learned about the crosslinking sites on 
oxyhemoglobin. Acyl groups with 2 or 3 carbons in the chain are more reactive 
than those with longer carbon chains of 4 to 1 O methylene groups 11 • 13 (see Table 
1 ). However, the compounds with longer chains permeate the red cell 
membrane easier than those with shorter carbon chains. 13 Diaspirins, whether 
TABLE 1 





















Source:R.H. Zaugg, J.A. Walder, R.Y. Walder, J.M. Steele, and l.M. 
Klotz. Modification of Hemoglobin with Analogs of Aspirin. J. Biol. Chem. 
255: 2816-2821 (1980). 
b Bridge between aspirin groups 
c % Cross-linked is the percentage of hemoglobin 13 chains that are 
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brominated or not, are more reactive than monoaspirins. 13 Bromination of the 
aromatic ring helps transport the ligand across the membrane. 13 In addition, 
since bromine is an electron-withdrawing substituent, nucleophilic attack by a 
hemoglobin amine group on the carbonyl group is facilitated. 13 Unsaturated 
chains have a higher percentage of crosslinking compared to saturated chains, 
which can be attributed to the inductive effect of the olefin which increases the 
!ability of the ester. 15 
These data explain why bis-(3,5-dibromosalicyl)fumarate (DBSF) 6 is able 
to crosslink oxyhemoglobin. DBSF is a diaspirin with a two carbon chain length. 
The bromine substituents aid in crossing the cell membrane, and the electron-
withdrawing nature of the substituents improves nucleophilic attack on the 
carbonyl group. Also, DBSF has an unsaturated chain which increases the rate 
of crosslinking. 
Polyphosphates 19• 24-26 are another group of crosslinkers which have been 
used. The proposed crosslinking site of bis-pyridoxal polyphosphates (Table 2) 
is from the N-terminal amine on one beta subunit to the ps2 lysine on the other p 
subunit. 19· 26 Benesch and coworkers varied the number of phosphate groups 
between two pyridoxal rings to determine the effect on crosslinking. 1 9 
Surprisingly, the 4 phosphate groups between pyridoxal rings resulted in a 
TABLE 2 









Methylene diphosphate 53 
Fructose 1 ,6-diphosphate 41 
2 ,3-diphosphog lycerate 70 
CH(=O) 
OH 
Source: R.E. Benesch and S. Kwong. Bis-Pyrjdoxal Polyphosphates: A 
New Class of Specific lntramolecular Crossljnkjng Agents for 
Hemoglobin. Biochem. Biophys. Res. Commun. 156: 9-14 (1988). 
a % Tetramer: Covalent lntramolecular Crosslinking of 
Deoxyhemoglobin by the Bis-Pyridoxal Polyphosphates 
11 
12 
recovering of 68% of the crosslinked tetramer. 19 This ligand is clearly much 
longer than the 11 A distance observed in the X-ray structure between the N-
terminal amine and ~282 lysine. One possible explanation is that the pyridine 
rings of the ligand must interact with each other. Thus, hemoglobin crosslinked 
with this class of compounds could be considered as a blood substitute since 
there is a very high yield of crosslinked tetramer, and experimentally it was 
determined to have a low oxygen affinity. 
The initial work of Abraham and coworkers was in antisickling agents7· 8 
with later efforts in the allosteric modification of hemoglobin.9· 27· 28 Many of 
these allosteric modifiers are not crosslinking agents, however they do bind at 
specific sites in hemoglobin. Allosteric modifiers affect the preferred 
conformation of the hemoglobin molecule in the same way as the biological 
allosteric effector molecule, BPG. 
The first nonnatural allosteric inhibitor reported by Abraham was clofibric 
acid (CFA) 7.7 The binding sites of CFA were determined by both X-ray and 
solution-binding studies.28 CFA binds in deoxyhemoglobin in two primary (high 
occupancy) sites, between the a subunits, and two secondary (low occupancy) 






Perutz and Poyart discovered a more potent allosteric inhibitor, 
bezafibrate (BZF) 8.27 BZF occupied one of the primary sites, and also one of 
the secondary sites filled by CFA. Lalezari and coworkers reported that 
analogues of BZF, urea derivatives, 9, were even more potent allosteric effectors 





b = 3,5 - Cl 
c = 3,4,5 - Cl 
9 
COOH 
These derivatives were also found to bind in a similar manner as BZF. Abraham 
and coworkers then reported on three series of compounds, 10-12, similar in 
structure to Perutz's compounds 8 and 9, which also are allosteric effectors. 28 10 
and 11 occupy a binding site in the a subunits near lysine 99 of hemoglobin 





b = 3,5 - Cl 






a= 4 -Cl 
b = 3,5 -Cl 







Even more recently, mellitic dianhydrides29 13 have been shown to 
crosslink deoxyhemoglobin. These compounds decrease oxygen affinity, 
maintain much of the cooperativity of binding and reduce the Bohr effect. 
Interestingly, these compounds are believed to crosslink deoxyhemoglobin in the 






Goal of This Study 
The goal of this research was to use molecular modeling techniques to 
develop a molecule that would crosslink hemoglobin upon irradiation. In order to 
achieve this goal, the initial research effort was to examine hemoglobin, the sites 
where crosslinking is known to occur, and many literature references about 
crosslinking hemoglobin. The possible mechanism of crosslinking was explored 
using molecular dynamics and minimization experiments. After the simulation of 
binding of known crosslinkers, we then used various computer programs to 
develop a molecule which is suggested to crosslink deoxyhemoglobin between 
the a subunits. 
CHAPTER 2 
EXAMINATION OF HEMOGLOBIN 
Introduction 
Our initial goal was to gain familiarity and intuition into the binding and 
crosslinking of hemoglobin. 
Conformational Search of Djaspirin 
The research began with an examination of a known crosslinker in various 
sites of the deoxyhemoglobin22 and oxyhemoglobin30 X-ray crystal structures 
from the Brookhaven Protein Database,31 2HHB and 1 HHO, respectively. The 
known crosslinker is bis-(3,5-dibromosalicyl)fumarate, or diaspirin (DBSF), 6, 
which crosslinks oxyhemoglobin at the pa2-pa2 residues. 15 
The conformation which DBSF adopts to bind to hemoglobin is unknown, 
therefore a conformational search was performed. The molecule was 
constructed in Chem-X,32 and its energy was minimized using molecular 
mechanics to remove any steric interactions. One hundred conformations were 
generated using a distance geometry program called Dgeom33, with the Chem-X 
minimized structure as the initial starting structure. 
Dgeom describes the structure of a molecule with a distance matrix for 
each pair of atoms in the molecule. The program uses a triangle inequality 
16 
17 
algorithm which sets up an upper bounds (maximum distance) and a lower 
bounds (lower distance) that is used for each pair of atoms, or distances from the 
starting structure. Through the use of this matrix, random conformations are 
generated. 
These conformations were then submitted to the program Reject.34 Reject 
compares distances between given atoms and based upon this comparison, 
duplicate conformations within an allowed tolerance are deleted. The atoms 
compared are shown in Figure 2 and the tolerance used was 0.2 A. Thirteen 
conformations were kept, and then minimized to reduce any steric hindrances 
using two different programs, Chem-X and Oiscover.35 The results from the 
minimization are given in Table 3, with the energies calculated by both programs. 
Both programs minimized the conformations in the gas phase due to the 
uncertainty in determining the dielectric constant and the solvent interactions. 
Nine out of the thirteen minimized conformations of DBSF, determined by 
either the Chem-X or Discover minimization, were a trans conformation (Table 3), 
the actual conformation of the reagent. It would seem reasonable that this low-
energy configuration is most likely to occur when binding to the hemoglobin 
protein. The differences in the energy values of the minimized conformations 
from the two programs are due to the different force fields and parameters used 
by each of the programs. 
Investigation of Hemoglobin Crosslinking Sites 
An exploration of oxy and deoxy hemoglobin was undertaken in an effort 
to gain some familiarity with the two conformations of hemoglobin and the sites 
where crosslinking either occurs or is thought to occur. Therefore, using one 
18 
FIGURE 2 


















































a The differences in the numbers between the two programs is due to 
the different force fields and parameters used in each program. 
b Unless otherwise specified, trans conformations are listed. The 
conformational names refer to the experimental codes. 
20 
conformation of diaspirin, dbbfxm87, and a minimization program, Discover, five 
different sites were explored in hemoglobin. This conformation of diaspirin was 
chosen because it was the lowest energy conformation calculated by Chem-X. 
Diaspirin is known to crosslink oxyhemoglobin between the carbonyl 
carbons of diaspirin and the ~-nitrogen atoms of the lysine residues positions at 
13 1a2-132a2.1s. 16 This compound is also known to crosslink in the same manner 
in deoxyhemoglobin between two lysines at the a99 sites.36· 37 There are three 
other sites in deoxyhemoglobin, 13182-13282, 13182-132132, 13182-1321, which are 
possible secondary sites for crosslinking to occur.37 All the sites involve two 
lysine residues interacting with the fumarate except for the 13182-1321 site; 131 is 
the N-terminal valine residue. Thus, the sole oxyhemoglobin site and the four 
deoxyhemoglobin sites were explored to elucidate why a crosslinker would bind 
in one site versus another. 
Using the oxyhemoglobin and deoxyhemoglobin crystal structures, the 
fumarate was manually placed in the particular protein site being examined. 
Bonds were made between the carbonyl carbon of the fumarate and the nitrogen 
atoms of the lysines on both sides of either the alpha or beta chains except for 
the 13182-1321 site in which bonds were made to the 1321 valine and the 13182 
lysine amine. Since it would be too computationally intensive, and of minimal 
utility, to minimize the entire hemoglobin tetramer, only a subset of atoms of the 
beta chain or alpha chain within 1 O A of the alpha carbon of lysine 1382 or a99 
were considered. Atom potentials and charges were assigned by the Insight 38 
program. The 1 O A subset was minimized in Discover allowing only the fumarate 
and lysine chains to move. The rest of the atoms were held fixed. The 
minimization used the conjugate gradients method35 until the root mean square 
21 
(RMS) derivatives were less than 0.01. Table 4 lists energies for the minimized 
subsets of atoms. 
Results and Discussion 
Figures 3 to 7 show the minimized structures at the various crosslinking 
sites. The results of the minimization experiments of the different sites 
corroborates the experimental results from the crosslinking experiments. 
Comparison of Figure 3 (oxyhemoglobin, pl 82-P2 82) and Figure 4 
(deoxyhemoglobin, cq99-a299) to Figures 5-7 (deoxyhemoglobin P182-P282, 
P182-P2132 and P182-P21, respectively), shows that the minimized conformations 
of the fumarates in the p-cleft of deoxyhemoglobin with p subunits crosslinked 
(Figures 5-7) are fully extended and the bond distances are slightly longer than 
normal bond lengths. The oxyhemoglobin at P182-P282 and deoxyhemoglobin 
al 99-a299 cross links are more relaxed and the conformations are more folded. 
From these results we suggest that the secondary crosslinking site in 
deoxyhemoglobin is the P182-P282 site. This conclusion was obtained after 
consideration of the distance between binding points in each site and when 
fumarate is bound, how it is oriented and how stretched the bonds are. The 
distance of the deoxy Pl 82-P282 site were closer in length (9.33 A) to the known 
crosslinking binding sites of deoxy a199-a299 (7.82 A) and oxy P182-P282 (10.73 
A). Also, the energy of the minimized structure of the deoxy Pl 82-P282 site (1.90 
Kcal.) was lower then either of the deoxy Pl 82-P21 (35.96 Kcal.) or P1132-P282 
(60.05 Kcal.) sites. An argument against the secondary binding site suggestion 
is that no crosslinked pa2 in deoxyhemoglobin has ever been isolated. 39 
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FIGURE 3 
Minimization of crosslinked oxyhemoglobin: ~182-~282 site. 
The distances between each atom of the crosslink are measured. 

FIGURE 4 
Minimization of crosslinked deoxyhemoglobin: a199-a299 site. 





Minimization of crosslinked deoxyhemoglobin: J3182-J3282 site. The 
distances between the atoms of the crosslink are measured. 

FIGURE 6 
Minimization of crosslinked deoxyhemoglobin: ~l 82-~2132 site. 





Minimization of crosslinked deoxyhemoglobin: ~182-~21 site. 
The distances between the crosslinked atoms are measured. 
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The results of this portion of the research demonstrated why one 
molecule, DBSF, crosslinks at these sites. It also suggested a potential 
secondary site. Thus, this theoretical experimentation verified previous 
experimental work and provides insight regarding binding and crosslinking. 
Oxy: P182-P282 
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*The distances measured are from the X-ray crystal structures from non-
crosslinked hemoglobins before any minimizations were completed. 
CHAPTER 3 
MINIMIZATION OF OXY AND DEOXY HEMOGLOBIN 
CROSSLINKED WITH DBSF 
Introduction 
Chapter 2 discussed the orientation of the DBSF ligand, after crosslinking 
both deoxy and oxy hemoglobin at various sites. These calculations allowed only 
the fumarate and lysine chains to move during minimization with the remainder of 
the protein held fixed. It would be of interest to examine the crosslinked 
hemoglobins after minimization of the entire crosslinked protein and to determine 
where changes occurred in the protein. 
Methodology 
The X-ray crystal structure of deoxyhemoglobin22 from the Protein Data 
Bank31 ,(2HHB) 1.7 A resolution, was used as the starting structure. DBSF was 
manually placed an approximately equal distance (3.32 A and 3.26 A) from the 
~82 lysine side chain amine groups using the lnsight35 program. Bonds were 
made between the ~82 lysines and the ester carbonyls after the 3,5-
dibromosalicyl rings were removed. The crosslinked protein was then minimized 
using the conjugate gradient algorithm in the Discover program for 1 O X 100 
iterations, holding the mainchain atoms (alpha carbons, carbonyls, and nitrogens) 
fixed and allowing only the sidechains to move. Discover also has a method of 
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restraining, or tethering, the atoms of a protein to their initial coordinates. In 
order to minimize major movements of the protein a user-defined force constant, 
which controls the strength of the tethering, can be invoked and then decreased 
gradually in steps. Therefore, upon completion of this first set of minimizations, 
the mainchain was tethered with a force constant of 500 Kcal/A for 1000 
minimization iterations. The force constant was decreased to 250 Kcal/A and 
another 1000 iterations were performed. This process was continued with 
decreasing force constants of 175, 100, 25, and O Kcal/A with 1000 iterations at 
each force constant value. The total computer time was 27 hours on a VAX9000. 
The oxyhemoglobin X-ray crystal structure30 was also minimized with the 
DBSF ligand crosslinked at the j382 lysines. The same procedure as described 
above was used for deoxyhemoglobin. The cpu time for this minimization was 28 
hours on a VAX9000. 
A final "control" minimization experiment was to minimize both the native 
oxy and deoxyhemoglobin protein exactly as the model crosslinked proteins, as 
has previously been described This was performed so that a direct comparison 
could be made between the minimized crosslinked protein to the minimized 
uncrosslinked native protein. 
Results of Minimization 
The final crosslinked deoxyhemoglobin structure after minimization was 
superimposed upon the original native X-ray crystal structure8 using the Insight 
program. An RMS deviation of 1.18 A was found after superimposing the C-
alpha atoms. A superposition of all backbone atoms gave an RMS deviation of 
1.19 A. Using the Abbott programs, Histplt and Distplt,40· 41 the distance 
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difference for each residue was calculated (Figure 8) and a histogram of the 
number of residues which occur at a specified interatomic distance was also 
calculated (Figure 9). 
The minimized crosslinked and uncrosslinked deoxyhemoglobin proteins 
were superimposed upon each other with a carbon alpha RMS deviation of 1.23 
A. The pa2 positions had moved more than most sections of the structure. 
However, the largest changes in the minimized crosslinked structure were not at 
the pa2 positions. The same plots of the distance difference for each residue 
(Figure 10) and the histogram of the number of residues which are at certain 
interatomic distances were also calculated (Figure 11) for these two proteins. 
The minimized oxyhemoglobin crosslinked structure was superimposed on 
the X-ray crystal structure30 with an RMS deviation of 1.47 A between all alpha 
carbons. There was also a 1.47 A deviation between all backbone atoms. When 
only one a helix of the X-ray structure is compared with the crosslinked 
minimized structure, an RMS deviation of only 0.97 A was measured. This 
suggests that the loop region residues have altered the most. The distance 
difference for each residue and the number of residues which occur at a specified 
interatomic distance were also calculated (Figures 12 and 13 respectively). 
The superposition of the minimized pa2 crosslinked oxyhemoglobin with 
uncrosslinked minimized oxyhemoglobin was completed with an RMS deviation 
of the C-alpha's being 1.36 A. Figure 14 is the distance difference for each 
residue and Figure 15 is a histogram of the occurrence of residues at each 
interatomic distance. As in deoxyhemoglobin, the pa2 residues did not show the 
greatest movement. Residue (55) of the a chain moved the most. 
The RMS deviation measured between the crystal structure and the 
minimized crosslinked structure, and also for the minimized crosslinked and 
FIGURE 8 
Differences between C-alpha atom positions of pa2 crosslinked 
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Differences between C-alpha atom positions of J382 crosslinked 
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uncrosslinked proteins, were acceptable for both oxyhemoglobin and 
deoxyhemoglobin.42 A small RMS deviation (for example 0.2 A) would indicate 
only a small change has occurred after minimization. However, hemoglobin is 
large and has different structural features (a. helicies).3 These secondary 
structure features would be expected to maintain their conformations. The loop 
residues between these features would be expected to vary more after 
minimization. The minimization did not include solvent interactions which would 
aid in holding the loop regions and end residues in a fixed position. We were not 
overly concerned that there was some movement of residues, since the RMS 
deviation was less than 5.0 A. Also, the crosslinked deoxyhemoglobin structure 
did not minimize to a conformation similar to the oxyhemoglobin X-ray structure. 
The RMS deviation of the crosslinked deoxyhemoglobin structure to the X-ray 
structure of oxyhemoglobin for the alpha carbons was 2.56 A and for the 
mainchain atoms (carbon alphas, carbonyls, and nitrogens) was also 2.56 A. 
Therefore, the deoxyhemoglobin structure did not minimize to the oxyhemoglobin 
conformation. 
One interesting observation for deoxyhemoglobin is that there was a 
greater movement of residues for the crosslinked protein when compared with 
the uncrosslinked minimized structure (Figure 10) rather than with the X-ray 
structure (Figure 8). This was just the reverse situation for oxyhemoglobin when 
Figures 12 and 14 are compared. At present, there is no reasonable explanation 
of why there is this difference. The RMS deviations were reasonable for any of 
these comparisons. Preliminary X-ray crystallographic results for the deoxy ~82 
crosslinked hemoglobin43 also indicate that this structure is more similar to 
normal deoxyhemoglobin than it is to oxyhemoglobin. This is consistent with the 
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results presented here. A complete comparison of these two models will be done 
when the final X-ray coordinates are available. 
CHAPTER 4 
MOLECULAR DYNAMICS EXPERIMENTS 
lntroductjon 
There are a number of groups who have studied hemoglobin using 
molecular dynamics experiments.42• 44-48 Michael Johnson and coworkers,42 
along with Martin Karplus and associates,44 used molecular dynamics to study 
the movement of sickle and hemoglobin A in order to compare flexibility of the 
two structures. This chapter will describe the molecular dynamics experiments 
that were performed to decipher the possible mode of interaction of a crosslinker, 
DBSF, with oxyhemoglobin. This mechanism is believed to be typical for many 
other crosslinking reactions. 
Methodology 
A molecular dynamics experiment was utilized in order to investigate the 
possible movement of the ligand in the binding site. The programs employed 
were lnsight35 and Discover. The DBSF ligand was manually oriented in the 
BPG binding site (~ 182-~282) of oxyhemoglobin30 using the Insight program. 
One of the carbonyl carbons of the ligand was bonded to the nitrogen of lysine 
~82 as if it had reacted at this site. A subset was created that was 15 A from the 
center of the ~82-~82 site. This subset is further subdivided into three volumes 
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when running the molecular dynamics: 1) the residues 15 - 13 A from the center 
of the ~82 oxyhemoglobin site were held rigid, 2) the residues from 13 - 8 A were 
tethered (allowed to move slightly but somewhat restrained to their original 
position), and 3) the residues within 8 A to the center were allowed to move 
freely. These constraints allowed the ligand and protein within 8 A from the 
center to move and change conformation in order to avoid repulsive contacts and 
to simulate motion that occurs when DBSF binds in this site. All hydrogens were 
used in the molecular dynamics; the ionizable residues were used in the charge 
states seen at pH 7.0. In addition, if creation of this 15 A subset resulted in 
partial residues, the entire residue was included in the subset. 
The attached ligand and the side chains that were allowed to move in the 
oxyhemoglobin 8 A subset were minimized for 100 iterations. This was in order 
to remove repulsive contacts between the ligand, which had been manually fitted 
into the protein, and the protein itself. The temperature of the system was 
allowed to adjust to 300 K after 1000 iterations of molecular dynamics 
equilibration. Discover has an algorithm that adjusts temperature by scaling 
velocities. If the temperature is far from the temperature set for equilibrium, the 
velocities are increased vigorously until the temperature is met. The temperature 
was kept constant using another algorithm that varies the temperature slightly, as 
if the system were coupled to a heat bath, for the remainder of the dynamics 
calculations. The molecular dynamics experiment used the Verlet algorithm.35 
The initial experiment was set up so that the dynamics ran for 1000 iterations 
using a time step of 1 femtosecond, for a total of 1 picosecond. Every tenth 
iteration was written out to a file which was later loaded into the Insight program 
to make a movie for a visual depiction of the atom movements. 
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Modifications on thjs Experiment 
The initial dynamics experiment was modified several times in order to 
address specific mechanistic and procedural questions. In the first modification, 
the temperature was gradually increased by 20° increments from the initial 
temperature of O K, and allowed to run for 100 iterations after each increment 
until a temperature of 300 K was reached. The 1000 iterations of molecular 
dynamics then followed this gradual equilibration. This experiment determined 
whether there would be a change in the motion and distance of the lysine ~82 to 
the attached ligand if the temperature was gradually equilibrated or set at a 
specific temperature. 
In a second modification the charge on the ~82 lysine amino group that 
was interacting with the bound DBSF ligand was varied. In the initial experiment, 
the lysine amine was positively charged while the acid substituent on the ligand 
was negatively charged, simulating a physiological pH of 7.0. Therefore, the 
charged species would be attracted toward each other. In a separate 
experiment, the lysine residue on the protein was deprotonated so it has a 
neutral charge and the molecular dynamics experiment was recalculated. 
Another modification to the molecular dynamics experiment lengthened 
the number of iterations from 1,000 to 100,000 with both the charged and neutral 
ligands bound to one ~82 lysine. Every 1 OOth iteration was written to a file for 
each run. This experiment explored the frequency of the bound ligand coming in 
close contact with the crosslinking ~82 lysine. 
The last modification to this experiment changed the subset specification 
on the charged lysine experiment in order to determine whether a larger subset 
of moving residues would result in a different answer. A new subset was created 
to give a 25 A size, which was further subdivided into three volumes. The three 
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volumes were: 1) 25 - 16 A from the center was held rigid, 2) the residues from 
16 - 13 A were tethered, and 3) 13 A to the center was allowed to move freely. 
This experiment gave a 5 A radial increase to the volume of residues which were 
allowed to move freely rather than being tethered, compared to the initial 
experiment. 
Results 
The molecular dynamics experiments with DBSF bound to one side of 
oxyhemoglobin (1382) enables one to determine how the bound ligand could 
interact with the lysine j382 of the other subunit. The results of the experiment 
between the gradually equilibrated dynamics run versus a rapidly equilibrated 
system showed that the gradually equilibrated run allowed the bound ligand to 
interact more closely (Figure 16) with the j382 lysine than the fixed temperature 
equilibration (Figure 17). The gradual equilibration allows a better resolution of 
problems caused by bad contacts between the reagent and the protein and is 
probably a truer measure of the physiological state of the protein-ligand 
interactions. Therefore, all further molecular dynamics experiments were allowed 
to attain the equilibration temperature gradually, even at the expense of 
increased computer time. The computer time for the calculation increased on 
going from the fixed temperature regime (8 hours 52 minutes) to the slowly 
equilibrated system (11 hours 28 minutes) on a VAX 9000 computer. 
The second modification, which varied the charge on the j382 lysine amino 
group interacting with the DBSF ligand bound to the other j382 residue, showed 
that the charged species were attracted toward each other. The two groups that 
would make the crosslink are the charged lysine ~82 amino group and the ester 
carbonyl. The nearest distance between these groups was close 
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FIGURE 16 
Molecular dynamics with gradually equilibrated temperature of bound 
DBSF on oxyhemoglobin. After each 200 increment, 100 iterations of 
dynamics were performed until reaching 300 K. 1,000 iterations of 
molecular dynamics followed the gradual equilibration. The distance 
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Molecular dynamics at fixed temperature of bound DBSF on 
oxyhemoglobin. The temperature was set at 3000 and 1,000 










enough (3.5 A)49 for the crosslinking to occur. The distance averaged 
between3.5 - 6.0 A. It appears that the carboxylate on the aromatic ring attracts 
the lysine J382 and brings it sufficiently close for the crosslinking to occur (Figure 
16). 
This experiment was run three times and the closest contact between the 
neutral lysine J382 and the ester carbonyl was 4.11 A. This is too great a distance 
for a crosslinking to occur (Figure 18).49 Therefore, if the mechanism for 
crosslinking begins when one J382 lysine reacts with one ester carbonyl of DBSF, 
the negatively charged carboxylate group on the DBSF could aid the crosslinking 
with the other J382 lysine, by increasing the probability that the two reacting 
groups will be sufficiently close for reaction. It should be noted that the NH3+ 
lysine must still deprotonate prior to making the new bond. 
The third modification lengthened the number of molecular dynamics 
iterations from 1,000 to 100,000 with experiments for both the charged and 
neutral lysine J382. In the 100,000 iteration experiment, the neutral ligand 
averaged a distance of between 12 - 16 A between the J382 lysine and the ester 
carbonyl. The closest approach was approximately 5.5 A between the ligand and 
the lysine (Figure 19). The distance between the carbonyl and the charged 
lysine in the 100,000 iteration experiment averaged a distance of 5.0 - 6.5 A 
(Figure 20) with the closest contact being 4.8 A. The negatively charged ligand 
was attracted to the positively charged lysine as evidenced by the shorter 
distance of interaction. This result revealed that this interaction could occur 
frequently if this is the mechanism for crosslinking. It should be emphasized that 
both the short and longer molecular dynamics experiments agreed there is a 
greater possibility for the charged lysine to interact with the negatively charged 
ligand than the neutral lysine amine. 
FIGURE 18 
Molecular dynamics for 1,000 Iterations: Measuring the distance 
between the neutral ~82 lysine nitrogen and ester carbonyl 






































Molecular dynamics for 100,000 iterations: Measuring the distance 
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Molecular dynamics for 100,000 iterations: Measuring the distance 



















At this time, it can not be explained why there is a variation in the 
distances of interaction when comparing the shorter molecular dynamics runs 
and the longer one. One possible way to resolve this would be to write the 
molecular dynamics coordinates to a file more frequently than every 100 
iterations. However, this was not done because the trajectory file where the 
coordinates were sampled every 100 iterations was already very large. 
In the last modification, the subset of atoms considered in the molecular 
dynamics experiments with a charged lysine was increased from 15 A to 25 A. 
We originally intended to perform 100,000 iterations, but unfortunately the VAX 
9000 crashed after about 40,000 iterations and the program was restarted for 
another 60,000 iterations. Thus the total iterations is 100,000 but the results will 
be shown in two parts: part a is the 40,000 iteration piece and part b is the 
60,000 iteration portion of the trajectory. The closest approach between the 
lysine amine and the ester carbonyl was 4.19 A for part a (Figure 21) and 3.91 A 
for part b (Figure 23). The interesting result is that the distance from the lysine 
amine to the acid oxygen on the dibromosalicyl part was only 2.5 A for both part 
a and b (Figures 22,24). 
The mechanism of crosslinking is thought to occur in a two step 
mechanism: 1) one side of DBSF reacts with one ~82 lysine of oxyhemoglobin 
and then, 2) the other ~82 lysine comes in close contact due to electrostatic 
interactions with the acid to complete the crosslink. However, at pH 7.0, the 
lysine would be charged and only the uncharged species would attack the 
carbonyl of the substrate. Therefore, we speculate that the carboxylate of the 
salicylate leaving group not only electrostatically attracts and orients the reactive 
lysine, but also deprotonates the ~-amino group, making it a better nucleophile. 
Both of these factors would increase the specificity and the speed of the 
crosslinking reaction. 71 
72 
FIGURE 21 
Molecular dynamics for 40,000 iterations: Subset size is 25 A 
measuring the distance between the protonated pa2 lysine nitrogen 
and ester carbonyl of bound DBSF. 
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Molecular dynamics for 40,000 iterations: Subset size is 25 A 
measuring the distance between the protonated ~82 lysine nitrogen 







































Molecular dynamics for 60,000 iterations: Subset size is 25 A 
measuring the distance between the protonated 1382 lysine nitrogen 

















Molecular dynamics for 60,000 iterations: Subset size is 25 A 
measuring the distance between the protonated ~82 lysine nitrogen 
and the salicylic acid. 
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THE DEVELOPMENT OF A PHOTOAFFINITY 
CROSSLINKER FOR HEMOGLOBIN 
Introduction 
The purpose of this portion of research was to design a molecule using 
molecular modeling techniques that would crosslink hemoglobin when irradiated 
by light. Chapters 1-4 described the characterization of the different crosslinking 
sites in hemoglobin and the possible mode of interaction. This chapter will 
describe the process involved in the development of a new crosslinker. 
There were several problems which needed to be addressed in order to 
develop a new crosslinker. The first problem was to find a computer program 
that could reproduce the binding of a known ligand in either deoxy or 
oxyhemoglobin. Abraham and associates examined the binding of bezafibrate 
and its analogues 8,10-1228 in the a99 site of deoxyhemoglobin. This paper 
included a description of the ligand binding sites and mentioned that the X-ray 
coordinates were available from the authors. We obtained one set of coordinates 
for 3,5-dimethoxybezafibrate, 14, from Abraham in the Protein Data Bank format 
(PDB coordinates: protein plus ligands bound). A second set of coordinates of 
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the bezafibrate analogues 8,10,11 mentioned in this article were obtained at a 





These coordinates were converted into an ASCII file, which was subsequently 
converted into PDB format using Chem-X so that it could be read into Insight. 
Our intention was to take a conformation of one of the bezafibrate analogues, 
and using the Dock program50-52 to reproduce the position of the ligand in the 
a99 deoxyhemoglobin site. 
In order to use the Dock program, several steps must be completed before 
the ligand can be docked into the protein site. Initially, the program Sphgen50-52 
generates clusters of spheres which characterize the receptor site. A second 
program, Distmap50-52 or Chemgrid,50-52 creates a grid of the receptor site so 
that a score could be calculated for the fit of the ligand within the receptor, using 
either contact or forcefield scoring. In the next step, the ligand is placed into the 
receptor site, and the fit evaluated based on either 1) contact or surface 
interactions, 2) contact scoring with Delphi electrostatic scoring, 3) force-field 
scoring (considers both steric and electrostatic interactions), or 4) a combination 
of contact and forcefield scoring. 
The protein coordinates, a site region (a subset of the protein) where the 
ligand may interact, and the ligand coordinates are used as input to the program. 
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The sizes for the regions chosen are either based upon the atoms the program 
could accommodate (the protein specification) or the region that best describes 
the interaction site of the ligand with the protein (the site subset). A larger site 
region increases the computer time, and also places spheres in regions where a 
ligand could not be accommodated, for example, on the outside of the protein. 
The PDB coordinates used were those supplied by Abraham for 14. All 
the waters and the heme groups were removed from the deoxyhemoglobin 
protein. The whole protein could not be used since the Dock program has a limit 
of 3,000 atoms. Therefore, a region of 25 A from where one of the ligands binds, 
containing 2,653 atoms (Figure 25) was used as the protein. The site subset, the 
region where the ligand is to be docked, contains the atoms within 15 A from 
where the ligand was found to bind (Figure 25). Charges were placed on the 
ligand, 14, and written as a Sybyl mol2 file53 (a file type which contains charges 
on the atoms to be used in docking the ligand) using the conformation as found in 
the X-ray coordinates. The ligand was moved away from the site where it was 
found to bind so as not to bias the results. The protein, subset and ligand were 
input into the Dock program and the binding orientations found were scored using 
both the contact and the forcefield method. 
The same procedure was followed for compound 1 Ob and for DBSF 6 in 
oxyhemoglobin but using only the forcefield method of scoring. 
Results of the Docking Procedure 
The dock procedure of the 3,5-dimethoxybezafibrate 14 analogue using 
contact scoring placed the ligand in the active site of the protein. The ligand fit 
into the open volume of the active site, however, the hydrogen bond interactions 
were not taken into account. 
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FIGURE 25 
Region used in the Dock program: 25 A for the protein, 15 A subset 
where BZF was found in Deoxyhemoglobin. The 25 A subset is 
colored blue. The 15 A subset is colored brown. 
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The dock run of 3,5-dimethoxybezafibrate 14 using the forcefield scoring 
method showed very promising results, when compared to the PDB coordinates 
sent to us by Abrahams. The forcefield energies ranged from -33.0 kcal/mol to 
224.0 kcal/mol with -33.0 kcal/mol energy being the best fit of the ligand in the 
site. There were over 1000 possible solutions in this site with energies between 
-33.0 and -22.0 kcal/mol. The range of solutions considered was then narrowed 
to be from -33.0 to -27.0 kcal/mol, and only the best sixty solutions were 
examined. Overall, the ligand docked within the same vicinity as found in the X-
ray structure and in some cases the solutions made better interactions with the 
protein than the position of the bound ligand observed in the crystal structure 
(Figures 26-27). The position of the ligand in the X-ray structure is questionable 
since the lysine of the protein extends through the phenyl ring of the ligand. 
One problem with the dock results mentioned above was that the docking 
orientation of the molecule was rotated by 180 degrees compared to the X-ray 
structure28 (Figures 26-27). However, since only Van der Waals and electrostatic 
interactions of the ligand and protein are used in the scoring value and this does 
not include the effects due to water, solvent and other influences, this method 
appeared to validate the simulation of a ligand bound in a protein. It is possible 
that the orientation of the ligand found in the X-ray structure could be in the 
higher energy solutions which were not examined, since many solutions were 
found for a small range (recall over 1 ,000 solutions for the range of -33.0 to -22.0 
kcal/mol). The forcefield scoring method can only approximate the true 
interactions. 
It should be mentioned that the a99 site being examined has a C2 
symmetry axis in which Abraham28 found a ligand bound in both halves of the 
protein. The Dock program gave a result in which a ligand was found to fit in 
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FIGURE 26 
Dock of dimethoxy compound 14: X-ray structure versus the 
docked structure in a99 site of deoxyhemoglobin. The X-ray 





Dock of dimethoxy compound 14: X-ray structure versus the 
docked structure which is in a better position in the a99 site of 
deoxyhemoglobin. The X-ray structure is colored red and the 
docked molecule is colored blue. The distance was measured 
between the lysine nitrogen and either the methoxy oxygen in the 
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either half of the protein site around the a99 lysine. The program does not have 
the capability of placing two ligands in the site at the same time. So it was 
gratifying to find both possibilities present in the 60 solutions that were examined. 
The docking of 3,5-dichlorobezafibrate analogue 1 0 b into 
deoxyhemoglobin was also completed using the conformation of the ligand seen 
in the X-ray structure. 28 The forcefield energy scores ranged from -32.87 
kcal/mo! to greater than 245 .91 kcal/mol. Only the orientations with energy from 
-32.87 to -29.00 kcal/mo! were examined. These docking results were better 
than the previous docking of 3,5-dimethoxybezafibrate since these results 
showed the correct orientation, some solutions were even superimposed on the 
X-ray crystal structure of the ligand (Figure 28). As before, the ligand was placed 
in both halves of the protein as was found in the X-ray crystal structure. This 
further validated use of the Dock program in order to find the placement of a 
ligand in a chosen site. 
A third docking experiment used the DBSF ligand and examined its 
possible binding orientations within deoxyhemoglobin. Since the conformation in 
which DBSF binds in the protein is unknown, 100 conformations were generated 
in Dgeom and minimized within Chem-X. All 100 minimized structures were 
loaded into a Sybyl database and Gasteiger-Huckel charges54. 55 were placed on 
each conformation. The entire database of conformations with charges were 
written out as a mol2 file and converted into a database. This database was then 
specified for use in the Dock program. The Dock program took each 
conformation in this database and found the best fit within the specified protein 
site. The results indicated that many conformations were placed in the area 
where the crosslinking is known to occur experimentally (Figure 29). This was 
the first docking experiment in which the conformation of the ligand was 
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FIGURE 28 
Superposition of the X-ray structure versus the docking of 3,5-
dichlorobezafibrate 10b in the a99 site of deoxyhemoglobin. The 







unknown, and thus gave very encouraging results showing that the program 
would place the ligand where crosslink could occur. This is further validation that 
this program would give a good idea of the location that a molecule is likely to 
bind and could then crosslink within the site. 
De Novo Design 
Grid 
There are a few commercial programs that can help in designing new 
compounds for binding when the protein structure is known. One of these 
programs, Grid,56 was the first "de novo" program explored in this research for 
deoxyhemoglobin in the a99 site. 
Grid is a program designed to calculate energetically favorable sites in a 
protein depending on the specific probe used. 56 Grid employs the Lennard-Jones 
potential56 in which there is a certain distance that gives the most favorable 
interaction between two non-bonded atoms. A probe representing a molecule or 
particular property (for example a methyl group probes steric regions) is then 
moved throughout the protein. The potential energy, Exyz, of the probe 
iscalculated at the array of "grid points" that have been established throughout 
the protein. 
The protein we used is the subset of deoxyhemoglobin obtained from 
Abrahams (which is the same as the X-ray crystal structure),28 but only half of the 
a99 site was used since there is a C2 symmetry axis at the site. The water 
molecules and heme groups were removed from the protein. The probes used in 
these calculations were the water, hydroxyl, methyl, carboxy, and protonated 
amine probes. An array of energy values were calculated with each of the 
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FIGURE 29 
Docking of DBSF into the deoxyhemoglobin a99 site. DBSF is the 




probes and the energy values visualized using isoenergetic contours in Insight. 
Results from Grid 
The contours using each of the probes were examined and the range of 
energies listed for each probe (Table 5). These contours are very helpful in 
designing a new crosslinker for deoxyhemoglobin at the a99 site since it gives 
some indication where a bulky group (Me probe) may prefer to be or not be, or 
where some electronegative atom may be favorably placed, based upon the X-
ray crystal structure of deoxyhemoglobin.22 The contours for each of the probes 
are shown in Figures 30-34. 
Database Docking 
This is similar to the Docking method described previously. The Dock 
program searches a database of various structures, rather than using a database 
of one molecule with many conformations to be fit into the protein site, and ranks 
the compounds based on the scoring method chosen. 
The protein was the portion of the a99 deoxyhemoglobin tetramer 
encompassing the atoms within 25 A from the center of the site. The database 
initially searched was a small database of 200 compounds from the Cambridge 
Crystal Database of small molecule X-ray structures. This database allowed for 
a search using only the contact scoring method. Another database was created 
from the Available Chemicals Database ( ACD, 2,000 compounds)57 in which 
forcefield interactions were searched. The Gasteiger-Huckel charges had been 
calculated for these compounds. 
TABLE 5 
The Range of Energies for Each of the Probes Employed in the Grid Program. 
Probe Range of Energy (Kcal.) 
H20 - 9.69 to 5.00 
OH- - 8.54 to 5.00 
CH3 - 4.29 to 5.00 
coo- -19.29 to 5.00 
NH3+ -25.26 to 5.00 
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FIGURE 30 
Contour from Grid for the water probe. The red contour are places 
in the a99 deoxyhemoglobin site where water or a hydrophilic group 
would like to be placed. The energy range for this probe is from 




Contours from Grid for the methyl probe. The blue contours are 
where a methyl or hydrophobic group would like to be placed. The 
energy range for this probe is from -4.3 to 5.0 Kcal. and these 




Contours from Grid for the carboxylate probe. The magenta 
contours are where a carboxylate group would like to be placed. 
The energy range for this probe is from -19.3 to 5.0 Kcal. and these 




Contours from Grid for the hydroxyl probe. The orange contours 
are where a hydroxyl group would like to be placed. The energy 
range for this probe is from -8.5 to 5.0 Kcal. and these contours are 




Contours from Grid for the amine probe. The black contours are 
where an amine group would like to be placed. The energy range 




Results of Database Docking 
Using contact or forcefield scoring, the Dock program placed a number of 
molecules in the a99 deoxyhemoglobin site. Most molecules were not of interest 
since they were too large in size or very toxic. Two molecules that were of 
interest are 15 and 16, both of which came from the ACD database, are shown 
below. 16 was thought to be too large to fit into the site of interaction, however it 
suggested a molecule 17 similar to the diaspirin molecule with the ester 
orientation reversed compared to DBSF. One potential problem with 17 is the 














Azide groups were added in either the meta and para positions on both of the 
phenyl rings, thus creating two molecules to be examined, 18 and 19. 150 
conformations were generated with Dgeom for each of 18 and 19. We attempted 
to minimize these conformations with Chem-X. However, the azide group could 
not be minimized in Chem-X because there were no parameters available, 
therefore, an isocyanate (NCO) was substituted in its place, and all 
conformations were minimized. The conformations with the isocyanate 
substituent were loaded into Sybyl and Gasteiger-Huckel charges were placed on 
each conformation. These conformations for each molecule were written out into 
a mol2 file and then converted into a file that was converted to a Dock database. 
The Dock program was run for both molecules. 
0 
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Both Dock runs found a small number of conformations of the ligand which 
might interact in the a99 site of deoxyhemoglobin. But overall, it didn't seem that 
either molecule would have a driving force which would help to direct these 
molecules into the a99 site or keep it at that site. Therefore, these molecules 
were not pursued any further. 
Lu di 
Ludi58• 59 is a program, incorporated into Insight, which is designed for use 
in de novo design of new ligands for a protein. There are three steps in using 
Ludi: (1) calculation of interaction sites within the area of the protein that is 
chosen to be the binding site, (2) a search in the fragment library for pieces that 
will fit the protein site and (3) attaching or linking these fragments to form a new 
ligand. Each of these steps will be described in more detail. 
The polar atoms of the protein can form favorable hydrogen-bonds from 
acceptors and donors positioned within a small area near each of these polar 
atoms. The possible locations of these acceptors and donors within these areas 
are the interaction sites. The X-ray crystal structure for small molecules revealed 
that there was not just one specific point for hydrogen bonding to occur, but 
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rather a range of interaction points. There are four types of interaction sites that 
are created by Ludi: (1) H-donor, (2) H-acceptor, (3) lipophilic-aliphatic and (4) 
lipophilic-aromatic. Hydrogen bond interactions are represented by the H-donor 
and acceptor, while hydrophobic interactions are represented by the remaining 
two types of interactions. 
The second step in this process is fragment fitting. Ludi contains a library 
of fragments through which it searches to find those that can interact at the 
interaction sites. The fragments are chosen based upon the square of the 
distances between the atoms of the fragments and the interaction sites.60 Once 
a fragment meets these criteria, Ludi performs a root mean square superposition 
using the Kabsch algorithm.60 A fragment is acceptable when the RMS value is 
within user specifications (usually 0.2 A to 0.6 A). Ludi also ensures that there 
are no steric or repulsive electrostatic interactions between the fragment and the 
protein. Once the fragment has passed these requirements, the coordinates are 
then stored in PDB format to be recalled later. 
The final step in this procedure is the linking of the accepted fragments 
together or onto an already existing molecule. Ludi can position a fragment onto 
a hydrogen of the core fragment in an orientation that would be favorable for a 
bond to be made. A modified version of Ludi called Autobuild 61 can pick one 
acceptable fragment at random and make a bond. The number of fragments to 
be attached can be specified, varying from one to three. The program is iterative; 
a fragment can be added or built on to a ligand and the process repeated. 
Ludi and Dock Experimentation 
A subset of the deoxyhemoglobin protein was used in the Ludi run. The 
a99 region was of interest, therefore a subset of the protein, 20 A from one of the 
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a.99 lysine nitrogens, was created. Ludi searched within a radius of 12 A from 
this same a.99 lysine atom. Fragments with an RMS of 0.3 A or less were 
accepted. The search produced 89 possible fragments that fit within this area. 
Two fragments, 20 and 21, were of interest because multiple hydrogen bonds 









20 made hydrogen bonds to aspartate C126 and tyrosine 035 and 21 had 
hydrogen bonds to glutamate 0101 or aspartate 094. These fragments were 
then connected by a methylene group creating 22 and the molecule was 
minimized to remove any steric repulsions within the a.99 site. 200 conformations 









200 conformations were added to a Sybyl database and Gasteiger-Huckel 
charges were calculated for each conformation. These were all written into a 
mol2 file and converted into a Dock database. A Dock run was then submitted 
where the bisamidine database was used to place the molecule in the protein 
binding site. 
The results of this Dock run were very encouraging since most of the 
conformations were placed into the a99 site making many of the hydrogen bonds 
bisamidine so that photochemically-induced crosslinking would occur. After 
reviewing the literature,62-65 it was decided that an aryl azide would be a good 
candidate. The aryl azide was added onto the ligand along with a methyl group 
which was to represent a second crosslinking portion to be added later to the 
bisamidine 23. Gasteiger-Huckel charges were assigned to the ligand. Insight 
could not assign charges to the azide group. With the help of Dr. Tetsuro Oie, 
appropriate charges for an aryl azide were devised as shown on 24. 
H 




Dock of bisamide portion into the deoxyhemoglobin a99 site. The 
ligand is forming hydrogen bonds to the aspartic acid (2.05 A) on 
one side and an aspartic acid (1.69 A) and tyrosine residue (1.81 A) 
on the other side. 
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Charges on the nitrogens are as follows: N1 = -0.213, N2 = 0.091, and N3 = -0.036. 
24 
Unfortunately, when 23 was minimized to remove any steric interactions 
due to the addition of the aryl azide, Discover was unable to handle the azide 
group because of missing parameters. Therefore an amine group replaced the 
azide group on the phenyl and was minimized without problem. 200 
conformations of each of these two structures (n=1,2) 25 and 26 respectively, 
were generated for each molecule by Dgeom with the amine group replacing the 





Sybyl database where Gasteiger-Huckel charges were added. The 
conformations were written out into two separate mol2 files and converted into 
files that could be read by Insight. The Dock program was used to determine 
whether the compounds would fit into the cx.99 site. 
The results from these Dock runs showed that a number of conformations 
were placed in the cx.99 site. The major difference between 25 and 26 was that 
the molecule with n=2 (26) extended out of the pocket. Therefore, further work 
continued with compound 25. 
In order to examine whether this is the optimum placement of the azide, 
and amidine groups around the phenyl, seven other related ligands were 
examined (Figure 36). Each of these seven molecules had 200 conformations 
generated in Dgeom and minimized in Chem-X. All the conformations were input 
into a Sybyl database and Gasteiger-Huckel charges were placed on each 
molecule. The conformations were output into a mol2 file and converted into a 
Dock database. 
A Dock run was completed for each of the seven compounds. The 
outcome was different for each of 27-33. The best Dock results were from 30. 
Dock placed this ligand several times in the cx.99 site of deoxyhemoglobin, and 
made two to three hydrogen bonds with the residues within the site. This result is 
particularly encouraging since an attraction of the ligand to the binding site 
suggests that this ligand will be more likely to be in the active site where the 
photoactivated crosslink could occur. Compounds 27 and 31 also gave 
interesting results. Each had some conformations that were placed in the cx.99 
site and making one to three hydrogen bonds, although not as many as 
compound 30. Nevertheless, they would also be interesting molecules to pursue. 
32 and 33 did dock in the vicinity of cx.99, but very often were docked sideways or 
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FIGURE 36 


























backward with the aryl azide group in toward the center of the cavity rather than 
rotated 1800. 27 and 28 had some well-placed conformations but they were not 
making the desired hydrogen bonding interactions. 
The last step of the de novo design was to take a conformation of 30 and 




the best assurance that 34 would bind in the a99 deoxyhemoglobin site, 200 
conformations were generated and minimized using Dgeom and Chem-X 
respectively, with an amine group in place of the azide for the minimization. 
These conformations were loaded into a Sybyl database and the amine group 
was changed to an azide group. For each of these 200 conformations, the azide 
group was rotated 1800 and this conformation was also stored in the database. 
Therefore, the database contained 400 conformations of the ligand. Gasteiger-
Huckel charges were assigned for the atoms of each conformation and all 
conformations were written into a mol2 file. This mol2 file was converted into a 
Dock database and Dock was run. 
There were some interesting results in which ligand 34 was oriented in the 
protein site as had been designed (Figure 37). But there were many 
conformations in which the ligand was oriented reversing the positions of 
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FIGURE 37 




the azide and the salicyl groups. This could be due to the size of the salicyl 
portion negatively interacting with the a99 lysine side chains. Therefore, two 
things were modified: first the mono aspirin was replaced with a phosphate group 
and the procedure repeated with this compound. And secondly, since the lysine 
sidechains can move and we are dealing with a rigid protein site, the a99 lysine 
chains were removed and Dock was repeated using the same database of 
compound 34. 
The Dock results of the phosphate-substituted ligand showed that almost 
all the conformations were oriented very differently from what was desired. 
These results again may be due to the bulk of the phosphate group interacting 
with the a99 lysine sidechains. There was no difference in the Dock results of 
placing the conformations of 34 into a modified protein where an alanine residue 
replaced the lysine residue. There were still conformations that fit the site and 
made the appropriate hydrogen bonds. But many of the molecules were oriented 
with the azide and the salicyl in reverse positions. This is still a promising ligand 
because it was placed into the site at least occasionally making the correct 
hydrogen bonds and the azide and salicyl ring was placed in the correct 
positions. 
Results and Discussion 
The bisamidine compound, 34, is a good choice for a novel photoaffinity 
crosslinker. The amidine portion should form hydrogen bonds with the carboxylic 
acid sidechains of residues aspartic acid C126, D94 or glutamic acid D101 in the 
binding site. These interactions would help not only to direct the ligand into the 
site, but also to keep the ligand in this pocket. The mono-aspirin portion should 
crosslink with an a99 lysine residue. Then, with irradiation, the ligand should 
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crosslink with the residues near by. This crosslinker has the unique combination 
of two different methods of forming covalent bonds between the ligand and the 
protein. This molecule, which has been designed to interact specifically with one 
site of hemoglobin, represents an attempt to use the methods of molecular 
modeling to suggest new compounds to help develop a better blood substitute. 
Proposed Synthesis 
Figure 38 depicts a proposed synthesis for the photoaffinity crosslinker 34. 
The strategy for the synthesis of the bisamidine is to introduce the most reactive 
functionality, the phenyl ester, last. The amidine groups are introduced as late as 
possible. 
The synthesis begins by reaction of the bisester 35 with one equivalent of 
sodamide in order to prepare only the monoamide 36. The benzyl alcohol is 
oxidized to the carboxylic acid 37 by acidic chromium trioxidess. Treatment with 
Meerwein's reagents? (Me30BF 4) will both form the ester and the methyl imidate 
from the amide on 37. Treatment with base will form the nitrile on 37. The ester 
is then opened with sodium cyanide on 38. The acid is then converted to the 
acid chloride and this is used in a Friedel-Crafts68 reaction with nitrobenzene to 
form 39. The ketone from the product is deoxygenated by treatment with P 4S1 o 
and then Raney nickel to form 40. The nitro group is then converted to the 
diazonium group, using nitrous acid, which is then converted to the aryl azide by 
treatment with sodium azide forming 41. The ester is then hydrolyzed with 
lithium hydroxide to the acid forming 42. This is done to prevent formation of the 
amide in the next series of reactions. The nitriles are then converted to the 
amidines by any one of many techniques, such as treatment with carbon disulfide 
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and ammonia to give compound 42. The remaining task is to form the phenyl 
ester from dibromosalicylic acid and the benzoic acid using 
dicyclohexylcarbodiimide and dimethylaminepyridine as catalyst forming 43. The 
salicylic acid may need prior protection as the tert-butyl ester. Treatment with 
hydrochloric acid should cleave the acid-sensitive t-butyl ester and form the 
bisamide dihyrochloride 43. 
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FIGURE 38 
Proposed Synthesis of Photoaffinity Crosslinker 34 
NaCN 
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Chapter 2 examined the binding of a crosslinker, DBSF, at the active site 
of hemoglobin. A complete conformational search and minimization of DBSF 
was completed in order to better understand the types of conformations this 
molecule can achieve. Secondly, the sites where crosslinking is known, or 
thought to occur, in both deoxy and oxyhemoglobin were examined using 
minimization experiments of DBSF bound within the active sites of these 
proteins. In these minimization experiments, only the bound DBSF was allowed 
to move. It was through these experiments that an understanding was achieved 
of why crosslinking occurs at the P182-P282 site of oxyhemoglobin and the a199-
a299 site of deoxyhemoglobin. It was also concluded that the P182-P282 site in 
deoxyhemoglobin may be the secondary crosslinking site. 
Another experiment involved the minimization of the whole protein of both 
oxy and deoxyhemoglobin while crosslinked with DBSF. This experiment 
allowed the sidechain residues of the protein to move together with the bound 
DBSF. The results of this experiment showed that the a helices do not change 
greatly, however the loop regions change significantly. This is consistent with 
preliminary X-ray crystallographic results on deoxy P82 crosslinked hemoglobin. 
The molecular dynamics experiments of chapter four examined the 
movement of a crosslinker bound to one lysine residue in oxyhemoglobin, but it 
also suggested a possible mode of interaction. Several modifications of the 
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molecular dynamics experiments were made, such as lengthening the number of 
iterations of the experiment, changing the charges on the interacting lysines, and 
enlarging the subset so as to allow more residues to move. These experiments 
suggested a probable two step mechanism of crosslinking: 1) one side of DBSF 
binds to one ~82 lysine, and 2) then the other ~82 lysine comes in close contact 
with the remaining salicyl group because of the electrostatic interactions between 
the acid group on DBSF and the amino group of the lysine, to complete the 
crosslinking. Therefore, the molecular dynamics experiments demonstrated what 
may be happening in the protein in a more realistic manner rather than observing 
a static protein. 
The last portion of this thesis was devoted to developing a new 
photoaffinity crosslinker for hemoglobin. This was accomplished using a variety 
of commercially available software programs. The initial problem was to find a 
program which could reproduce the binding of a known ligand in hemoglobin. 
This was accomplished using the Dock program with bezafibrate analogues 
being placed into the a99 site of deoxyhemoglobin. The procedure to develop a 
new crosslinker involved the use of such programs as Grid and Ludi. After the 
new ligand was developed, it was docked into the deoxy a99 site to examine the 
feasibility of binding in this site. The ligand was placed in the proposed site 
several times making the strong hydrogen bonds as initially proposed. This 
concluded an attempt to develop a new photoaffinity crosslinker for hemoglobin 
using molecular modeling techniques. 
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